Portable and Wearable Medical Devices: A Nanotechnology Approach

Speaker

Abstract

Point-of-care testing (POCT) is destined to play a much greater role in chronic disease diagnosis and management. Advanced POCT systems are being developed to deliver less costly and more acute healthcare in a patient’s home, but remain scarce. Especially lacking are miniature devices, similar to the commonly used blood glucose meter, to quantitatively detect low concentrations of protein biomarkers in blood. Here, a unique integrated system solution is presented, which represents a significant step beyond proof-of-concept high sensitivity nanosensors, for quantitative reading of b-type natriuretic peptide (BNP) in outpatient blood. BNP is an established biomarker for early heart failure (HF) diagnosis and prognosis. HF is an epidemic affecting more than 26 million people worldwide and a chronic disease with ever increasing prevalence. Currently, accurate and quantitative BNP blood tests are only available in central laboratory and emergency room using venous blood. Highly sensitive carbon nanotube thin film (CNT-TF) impedance sensors are integrated into a user-friendly POCT system, NanoBot, which consists of two parts: a disposable test strip and a miniature electrical readout unit. Using electrochemical impedance spectroscopy (EIS), combined with standard addition, NanoBot is demonstrated to detect blood BNP with a limit of detection (LOD), precision, and accuracy comparable to those of a standard immunofluorescence assay (IFA) and a commercial emergency room POCT device. A pilot clinical study with patient-derived blood plasma validates that NanoBot has not only strong performance, but also other advantages such as low sample volume, label-free and wash-free detection. Collectively, NanoBot’s performance and operational characteristics signify its promising potential as a POCT device for home-use heart failure diagnosis.

Learning Objectives:

1. Various aspects of electrochemical immunosensors for high-sensitivity detection of protein biomarkers

2. Recent advances and challenges in developing nano-biosensors

3. The need for disruptive technology to make the change from centralized healthcare to distributed healthcare


Show Resources
You May Also Like
FEB 15, 2023 7:00 AM PST
FEB 15, 2023 7:00 AM PST
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
OCT 13, 2022 9:00 AM +08
OCT 13, 2022 9:00 AM +08
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
SEP 28, 2022 9:00 AM PDT
SEP 28, 2022 9:00 AM PDT
Date: September 28, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) While COVID-19 continues to be the most pressing diagnostic focus for clinical laboratories, HIV remains a serious g...
C.E. CREDITS
Date: October 25, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CEST) Candida auris is a multi-drug resistant yeast that continues to be a global threat for infection and transmission in h...
Loading Comments...
Show Resources